Health & Healthcare in America: From Economics to Policy
June 22 - 25, 2014
Menu
Start
Browse by Day
Browse by Topic
Author Index
Joel Hay
Professor
University of Southern California
Papers:
16 Cost effectiveness of adding bevacizumab to first line therapy of patients with advanced ovarian cancer
18 Pregabalin (Lyrica®) is cost-effective over Gabapentin (Neurontin®) as a First-Line Treatment for Neuropathic Pain (NeP) Management after Spinal Cord Injury (SCI)
20 Cost-effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Cost-effectiveness comparison of Denosumab and Zoledronic Acid in the treatment of Postmenopausal Osteoporosis
Evaluating the Impact of Marijuana Use on Metabolic Syndrome Using Data from the Continuous National Health and Nutrition Examination Survey
Provider Preferences for Interventions for Reducing Inappropriate Antibiotic Prescribing
A Behavioral Economics Multi-site Randomized Trial to Reduce Provider Antibiotic Overprescribing
Cost-effectiveness analysis of abiraterone and sipuleucel-T in metastatic castration-resistant prostate cancer
The Cost-Effectiveness of Screening and Management Strategies for Familial Hypercholesterolemia in the United States: A Markov Model Analysis
A COST-EFFECTIVENESS ANALYSIS OF PRE-EXPOSURE PROPHYLAXIS (PrEP) FOR THE PREVENTION OF HIV IN THE LOS ANGELES COUNTY MSM POPULATION
Cost-Effectiveness Analysis of Diagnostic Methods for Clostridium difficile Infection
Medical Cost Offsets from Prescription Drug Utilization among Medicare Beneficiaries
